Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins

NeuroToxicology

Volumn 31, Issue 4, 2010, Pages 399-402

  Paul, Ripon ^a   Pessah, Isaac N ^b   Gane, Louise ^a,c   Ono, Michele ^a,c   Hagerman, Paul J ^a,c   Brunberg, James A ^c   Tassone, Flora ^c   Bourgeois, James A ^c   Adams, Patrick E ^a,c   Nguyen, Danh V ^c   Hagerman, Randi ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Agent Orange; FMR1; Fragile X associated tremor ataxia syndrome; Hexachlorocyclopentadiene; Industrial chemical exposure; Premutation

Indexed keywords

2,4,5 TRICHLOROPHENOXYACETIC ACID; 2,6 TOLUENE DIISOCYANATE; AMITRIPTYLINE; DICHLOROMETHANE; DULOXETINE; GABAPENTIN; HEXACHLOROCYCLOPENTADIENE; MECLOZINE; NEUROTOXIN; PREDNISONE; PROPRANOLOL; THYROID HORMONE; TOLUENE DIISOCYANATE; UNCLASSIFIED DRUG; FMR1 PROTEIN, HUMAN; FRAGILE X MENTAL RETARDATION PROTEIN;

ADOLESCENT; ADULT; AGED; AGORAPHOBIA; ANAMNESIS; ANXIETY; ARTICLE; ATAXIA; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DEPRESSION; DIZZINESS; ENVIRONMENTAL EXPOSURE; EVENING DOSAGE; FACIES; FALLING; FECES INCONTINENCE; FEMALE; FIBROMYALGIA; FRAGILE X SYNDROME; HEADACHE; HEART ARRHYTHMIA; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MAJOR DEPRESSION; MALE; MIGRAINE; MULTIPLE SCLEROSIS; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPTIC NERVE ATROPHY; OPTIC NEURITIS; PAIN; PANIC; PARASOMNIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RESTLESS LEGS SYNDROME; SLEEP DISORDER; SOCIAL PHOBIA; SYNCOPE; TONIC CLONIC SEIZURE; TREMOR; TRINUCLEOTIDE REPEAT; URINE INCONTINENCE; VERTIGO; COMPLICATION; GENETICS; HETEROZYGOTE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ONSET AGE; TOXICITY;

ADULT; AGE OF ONSET; AGED; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROTOXICITY SYNDROMES; NEUROTOXINS;

EID: 77953540652     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2010.04.002     Document Type: Article

References (30)

1. Abdo K.M., Montgomery C.A., Kluwe W.M., Farnell D.R., Prejean J.D. Toxicity of hexachlorocyclopentadiene: subchronic (13-week) administration by gavage to F344 rats and B6C3F1 mice. J Appl Toxicol 1984, 4:75-81.
2. Ambrus J.L., Islam A., Akhter S., Dembinski W., Kulaylat M., Ambrus C.M. Multiple medical problems following Agent Orange exposure. J Med 2004, 35:265-269.
3. Arocena D.G., Iwahashi C.K., Won N., Beilina A., Ludwig A.L., Tassone F., et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 2005, 14:3661-3671.
4. Bourgeois J.A., Cogswell J.B., Hessl D., Zhang L., Ono M.Y., Tassone F., et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 2007, 29:349-356.
5. Bourgeois J.A., Coffey S.M., Rivera S.M., Hessl D., Gane L.W., Tassone F., et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009, 70:852-862.
6. Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry; in press.
7. Capelli L.P., Goncalves M.R., Kok F., Leite C.C., Nitrini R., Barbosa E.R., et al. Fragile X-associated tremor/ataxia syndrome: intrafamilial variability and the size of the FMR1 premutation CGG repeat. Mov Disord 2007, 22:866-870.
8. Chen Y., Tassone F., Berman R.F., Hagerman P.J., Hagerman R.J., Willemsen R., et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 2010, 19:196-208.
9. Cho S.J., Jung J.S., Jin I., Jung Y.W., Ko B.H., Nam K.S., et al. Effects of 2,3,7,8-tetrachlorodibenzo-p- dioxin on the expression of synaptic proteins in dissociated rat cortical cells. Mol Cells 2002, 14:238-244.
10. Coffey S.M., Cook K., Tartaglia N., Tassone F., Nguyen D.V., Pan R., et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008, 146A:1009-1016.
11. Goetz C.G., Bolla K.I., Rogers S.M. Neurologic health outcomes and Agent Orange: Institute of Medicine report. Neurology 1994, 44:801-809.
12. Greco C.M., Tassone F., Garcia-Arocena D., Tartaglia N., Coffey S.M., Vartanian T.K., et al. Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. ArchNeurol 2008, 65:1114-1116.
13. Grehl H., Grahmann F., Claus D., Neundorfer B. Histologic evidence for a toxic polyneuropathy due to exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Acta Neurol Scand 1993, 88:354-357.
14. Hagerman P.J. The fragile X prevalence paradox. J Med Genet 2008, 45:498-499.
15. Hall D.A., Berry-Kravis E., Jacquemont S., Rice C.D., Cogswell J., Zhang L., et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005, 65:299-301.
16. Kim J.S., Lim H.S., Cho S.I., Cheong H.K., Lim M.K. Impact of Agent Orange exposure among Korean Vietnam veterans. Ind Health 2003, 41:149-157.
17. Kogan C.S., Turk J., Hagerman R.J., Cornish K.M. Impact of the fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated tremor/ataxia syndrome: a controlled study. Am J Med Genet B: Neuropsychiatr Genet 2008, 147B:859-872.
18. Leehey M.A., Berry-Kravis E., Min S.J., Hall D.A., Rice C.D., Zhang L., et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007, 22:203-206.
19. Morse D.L., Kominsky J.R., Wisseman C.L., Landrigan P.J. Occupational exposure to hexachlorocyclopentadiene. How safe is sewage?. JAMA 1979, 241:2177-2179.
20. O'Dwyer J.P., Clabby C., Crown J., Barton D.E., Hutchinson M. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 2005, 65:331-332.
21. Ott M.G., Diller W.F., Jolly A.T. Respiratory effects of toluene diisocyanate in the workplace: a discussion of exposure-response relationships. Crit Rev Toxicol 2003, 33:1-59.
22. Peters N., Kamm C., Asmus F., Holinski-Feder E., Kraft E., Dichgans M., et al. Intrafamilial variability in fragile X-associated tremor/ataxia syndrome. Mov Disord 2006, 21:98-102.
23. Rand G.M., Nees P.O., Calo C.J., Alexander D.J., Clark G.C. Effects of inhalation exposure to hexachlorocyclopentadiene on rats and monkeys. J Toxicol Environ Health 1982, 9:743-760.
24. Rand G.M., Nees P.O., Calo C.J., Clarke G.C., Edmondson N.A. The Clara cell: an electron microscopy examination of the terminal bronchioles of rats and monkeys following inhalation of hexachlorocyclopentadiene. J Toxicol Environ Health 1982, 10:59-72.
25. Roberts J.E., Bailey D.B., Mankowski J., Ford A., Sideris J., Weisenfeld L.A., et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B: Neuropsychiatr Genet 2009, 150B:130-139.
26. Rodriguez-Revenga L., Madrigal I., Al egret M., Santos M., Mila M. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 2008, 18:153-155.
27. Singer R., Scott N.E. Progression of neuropsychological deficits following toluene diisocyanate exposure. Arch Clin Neuropsychol 1987, 2:135-144.
28. Winneke G. The neurotoxicity of dichloromethane. Neurobehav Toxicol Teratol 1981, 3:391-395.
29. Young A.L., Giesy J.P., Jones P.D., Newton M. Environmental fate and bioavailability of Agent Orange and its associated dioxin during the Vietnam War. Environ Sci Pollut Res Int 2004, 11:359-370.
30. Zhang L., Coffey S., Apperson M., Agius M., Nowicki S.T., Tartaglia N., et al. Symptoms or diagnosis of MS in premutation females: a variant of fragile X-associated tremor ataxia syndrome (FXTAS)?. American Academy of Neurology 2005 Annual Meeting 2005.